Biocon Share Price Live
Live Biocon Share Price Chart
Biocon Performance
Days Range
| Previous Close | ₹395.15 |
|---|---|
| Open | ₹395.45 |
| Volume | 33,47,854 |
| Day's Range | ₹395.00 - ₹401.90 |
|---|---|
| 52W Range | ₹291.00 - ₹424.95 |
| Market Cap | ₹52,843.49 Cr |
Biocon F & O
Biocon Fundamentals
| ROCE(TTM) | 4.20 |
|---|---|
| P/E Ratio (TTM) | 69.34 |
| P/B Ratio | 1.97 |
| Industry P/E | 33.19 |
| Debt to Equity | 0.62 |
| ROE | 1.81 |
| EPS (TTM) | 3.51 |
| Dividend Yield | 0.11 |
| Book Value | 200.47 |
| Face Value | 5 |
| ROCE(TTM) | 4.20 |
|---|---|
| P/E Ratio (TTM) | 69.34 |
| P/B Ratio | 1.97 |
| Industry P/E | 33.19 |
| Debt to Equity | 0.62 |
| ROE | 1.81 |
|---|---|
| EPS (TTM) | 3.51 |
| Dividend Yield | 0.11 |
| Book Value | 200.47 |
| Face Value | 5 |
Biocon Financials
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | |
|---|---|---|---|---|
| Net Sales | 3,773.00 | 4,358.10 | 3,910.10 | 4,262.50 |
| Expenses | 3,495.00 | 3,775.10 | 3,648.00 | 3,933.10 |
| Profit before tax | 155.90 | 486.80 | 96.90 | 171.30 |
| Operating Profit | 81.10 | 459.40 | 89.20 | 132.80 |
| Net Profit | 81.10 | 459.40 | 89.20 | 132.80 |
| ESP in Rs | 0.16 | 2.75 | 0.26 | 0.72 |
Biocon Shareholding Pattern
| Held by | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|
| Promoters | 60.64% | 60.64% | 60.64% | 54.45% | 54.45% |
| Flls | 5.93% | 5.66% | 5.66% | 6.04% | 6.61% |
| Dlls | 14.44% | 15.37% | 15.72% | 22.82% | 22.1% |
| Public | 19% | 18.34% | 17.97% | 16.68% | 16.83% |
About Biocon
Biocon Limited was incorporated in 1978 as Biocon India Private Limited. In 1979, it became the first Indian company to manufacture and export enzymes to the USA and Europe. The company incorporated BCZ (BioChemizyme India) in 1982 to focus on research and development in relation to enzymes. It enhanced its in-house research programme, based on a proprietary solid substrate fermentation technology, from the pilot to the plant level in 1990.
The company leveraged its technology platform to enter biopharmaceuticals and statins in 1996. In 2004, the company went for an IPO to raise ₹300 crore to fund its huge capital expansion plans. As a result, it was listed on BSE and NSE.
After 4 years, Biocon acquired a 78% stake in German pharmaceutical company AxiCorp GmbH for a consideration of €30 million in 2008. In the same year, it became the 7th largest biotech employer in the world by Med Ad News. In 2013, the company entered into a partnership with Mylan through strategic collaboration for insulin products. Syngene (CRO Arm of Biocon) got listed on BSE and NSE in 2015.
In 2023, Kiran Mazumdar-Shaw was honoured with the G20 Healthcare Commitment Awards 2023 at the 21st Asian Business and Social Forum 2023 and The Healthier India Conclave 2023.
Business Segments
- Generics: The company manufactures and supplies innovative and affordable generic bulk drugs and finished formulations under this segment.
- Biosimilars: The company operates this business through Biocon Biologics Limited (BBL), a leading global biosimilars player with established capabilities in developing, manufacturing and commercialising biosimilars.
- Novel Biologics: It is actively involved in innovating novel assets for autoimmune diseases and cancer. The company rolled out Nimotuzumab (India’s first indigenously manufactured monoclonal antibody) for head and neck cancer in 2006.
- Research Services: The company run this business through Syngene, which has established itself as a leading global organisation offering integrated discovery research, development and manufacturing services.
Subsidiaries
As of March 31, 2023, the company had 26 subsidiaries and few of the subsidiaries listed below:- Syngene International Limited: It is a subsidiary of Biocon. The company provides services that include integrated drug discovery and development capabilities in chemistry, biology, vivo and vitro pharmacology, etc.
- Syngene USA Inc: It is a wholly owned subsidiary of Syngene, incorporated in 2017. It provides business and sales support services to the operations of Syngene in the USA.
- Syngene Scientific Solutions Limited (SSSL): It is a wholly owned subsidiary of Syngene. It is engaged in Contract Research and Manufacturing Services (CRAMS) and Clinical research services.
Key Personnel
Kiran Mazumdar-Shaw, Executive Chairperson – Biocon Limited and Biocon Biologics Limited Kiran Mazumdar-Shaw started her journey in 1978 from her garage in India. She is a first-generation entrepreneur and global business leader with an experience of more than 4 decades in biotechnology. She has been chairperson of the Board of Directors since its inception. Corporate Actions In 2019, the company announced a bonus issue of 1:1 with a record date of June 12, 2019. In 2017, Biocon announced a bonus issue of 2:1 with a record date of June 15, 2017. Management Outlook- For the generics segment, the growth drivers include enhanced capacities in its API business, growth in the volume of its base business and traction from its recently launched generic formulation products.
- The priorities for the generics business revolve around increasing the market share in existing products and new product launches, especially in the US.
SWOT Analysis
Strengths- Diversified revenue stream.
- First-mover advantage in the biologics business.
- Lack of technology implementation.
- Rising consumer disposable income.
- International business opportunities.
- Intense competition from peers.
- Changing climate scenario.
Parent Organisation
Indian Private
Managing Director
Kiran Mazumdar Shaw
Founded
1978
NSE Symbol
BIOCON
Top Mutual Funds Invested in Biocon Share
Top Mutual Funds Invested in Biocon Share
Peer Comparison
Peer Comparison
| Stocks | LTP (₹) | Market Cap (cr) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 1,779.5 2.10 (0.12%) | ₹4,26,565.77 | 1,548.0 - 1,910.0 |
| Divis Laboratories Ltd | 6,379.0 -83.50 (-1.29%) | ₹1,71,593.58 | 4,955.0 - 7,071.5 |
| Torrent Pharmaceuticals Ltd | 3,681.6 -39.80 (-1.07%) | ₹1,25,819.90 | 2,886.45 - 3,882.2 |
| Cipla Ltd | 1,512.1 -17.10 (-1.12%) | ₹1,23,504.18 | 1,335.0 - 1,673.0 |
| Dr Reddys Laboratories Ltd | 1,242.5 -6.10 (-0.49%) | ₹1,04,131.51 | 1,020.0 - 1,405.9 |
| Zydus Lifesciences Ltd | 924.7 -3.30 (-0.36%) | ₹93,338.26 | 795.0 - 1,059.05 |
Popular stocks
Biocon Ltd FAQs
What is the share price of Biocon Ltd (BIOCON) shares?
Biocon Ltd (BIOCON) share price as of November 21, 2025, on NSE is Rs 396.85 (NSE) and Rs 396.85 (BSE) on BSE.
Can I buy Biocon Ltd (BIOCON) from Angel One?
Yes, You can buy Biocon Ltd (BIOCON) shares by opening a Demat account with Angel One.
How do I buy Biocon Ltd (BIOCON) from Angel One?
Biocon Ltd (BIOCON) share can be bought through the following modes:
1. Direct investment: You can buy Biocon Ltd (BIOCON) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Biocon Ltd (BIOCON) shares.
1. Direct investment: You can buy Biocon Ltd (BIOCON) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Biocon Ltd (BIOCON) shares.
What are the Subsidiaries that comes under Biocon?
The key subsidiaries that come under Biocon are Syngene International Ltd, Biocon Biologics Ltd., Biocon FZ ltd, Biocon Biosphere Ltd., Biocon Pharma Ltd, Biocon Academy, Biofusion Therapeutics Ltd., Biocon SA Switzerland, Biocon FZ LLC, UAE.
What is the total Asset of Biocon?
The total asset of Biocon is Rs. 20,342 Crores.
What is the main business of Biocon?
The main business of Biocon as India's largest biopharmaceutical company is to develop affordable biosimilars, generic formulations, and complex APIs. Its aim is to change the lives of individuals in over 120 countries by finding new and affordable ways to treat diabetes, cancer and autoimmune diseases.
